MARKET

XXII

XXII

22ND CENTURY
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.970
-0.130
-4.19%
After Hours: 2.990 +0.02 +0.67% 19:20 09/24 EDT
OPEN
3.040
PREV CLOSE
3.100
HIGH
3.070
LOW
2.905
VOLUME
1.22M
TURNOVER
--
52 WEEK HIGH
6.07
52 WEEK LOW
0.5626
MARKET CAP
483.32M
P/E (TTM)
-21.4751
1D
5D
1M
3M
1Y
5Y
Sundial vs. 22nd Century Group: Which Cannabis Stock Is a Better Buy?
StockNews.com · 3d ago
Cannabidiol Market Size Passed $7 Billion In 2020, Estimated To Grow At Over 35% CAGR Between 2021 And 2027 - Financial News Media
Palm Beach, FL - September 15, 2021 - FinancialNewsMedia.com News Commentary – The CBD isolate market has been growing even before the pandemic appeared. While some areas of the healthcare sector remain to be impacted, the CBD sales have increased since th...
MENAFN · 09/15 18:36
Top Pharmaceutical Stocks for Q4 2021
These are the pharmaceutical stocks with the best value, fastest growth, and most momentum for Q4 2021.
Investopedia · 09/14 16:51
Cannabis Stocks Gainers And Losers For September 13, 2021
GAINERS: Cipher Pharms Inc (OTC:CPHRF) shares closed up 13.17% at $2.13 with an estimated market cap of $56.4M.
Benzinga · 09/13 20:43
22nd Century Group's Return On Capital Employed Insights
Benzinga Pro data, 22nd Century Group (AMEX:XXII) reported Q2 sales of $8.37 million. Earnings fell to a loss of $6.64 million, resulting in a 28.41% decrease from last quarter.
Benzinga · 09/07 15:30
Innate Pharma, Adagio top weekly healthcare gainers, Acasti Pharma, Forte Biosciences trail
As September started, the healthcare stocks in the S&P 500 returned to post gains after a brief decline last week. Thanks mainly to health insurers, the S&P 500 Healthcare Sector Index
Seekingalpha · 09/04 02:37
MariMed, Hexo & Aurora Cannabis Among Top Cannabis Movers For September 1, 2021
GAINERS: cbdMd, Inc. (AMEX:YCBD) shares closed up 9.3% at $2.35 with an estimated market cap of $135.8M.
Benzinga · 09/01 22:20
Monday's Marijuana Stock Movers
GAINERS: Rhinomed (OTC:RHNMF) shares closed up 10.77% at $0.29 with an estimated market cap of $73.9M.
Benzinga · 08/30 22:58
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of XXII. Analyze the recent business situations of 22ND CENTURY through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average XXII stock price target is 6.33 with a high estimate of 7.00 and a low estimate of 5.00.
EPS
Institutional Holdings
Institutions: 163
Institutional Holdings: 49.53M
% Owned: 30.43%
Shares Outstanding: 162.74M
TypeInstitutionsShares
Increased
21
14.86M
New
36
3.10M
Decreased
36
3.77M
Sold Out
19
3.61M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Environmental Services & Equipment
+0.47%
Professional & Commercial Services
-0.23%
Key Executives
Non-Executive Chairman/Independent Director
Nora Sullivan
President/Chief Operating Officer
Michael Zercher
Chief Executive Officer
James Mish
Chief Financial Officer
John Franzino
Vice President
John Brodfuehrer
Vice President - Research & Development
Juan Tamburrino
Director of Investor Relations/IR Contact Officer
Mei Kuo
Independent Director
Clifford Fleet
Independent Director
Anthony Johnson
Independent Director
Michael Koganov
Independent Director
Roger O'Brien
Independent Director
Richard Sanders
No Data
About XXII
22nd Century Group, Inc. is a plant biotechnology company. The Company is focused on technology that allows increasing or decreasing the level of nicotine and other nicotinic alkaloids in tobacco plants, and levels of cannabinoids in cannabis plants through genetic engineering and plant breeding. It is engaged in various activities, including research and development of less harmful or modified risk tobacco products and tobacco plant varieties; development of X-22, a smoking cessation aid consisting of very low nicotine (VLN) cigarettes; manufacture, marketing and distribution of its RED SUN and MAGIC cigarettes; production of SPECTRUM research cigarettes for the National Institute on Drug Abuse (NIDA); contract manufacturing of third-party branded tobacco products, and research and development of plant varieties of hemp/cannabis, such as plants with low to no amounts of delta-9-tetrahydrocannabinol (THC), plants with high levels of cannabidiol (CBD), and other non-THC cannabinoids.

Webull offers kinds of 22nd Century Group Inc stock information, including NASDAQ:XXII real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, XXII stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading XXII stock methods without spending real money on the virtual paper trading platform.